NO180148B - Process for the preparation of foodstuffs which have a prophylactic and / or therapeutic effect upon repeated intake - Google Patents
Process for the preparation of foodstuffs which have a prophylactic and / or therapeutic effect upon repeated intake Download PDFInfo
- Publication number
- NO180148B NO180148B NO920260A NO920260A NO180148B NO 180148 B NO180148 B NO 180148B NO 920260 A NO920260 A NO 920260A NO 920260 A NO920260 A NO 920260A NO 180148 B NO180148 B NO 180148B
- Authority
- NO
- Norway
- Prior art keywords
- vitamin
- fruit
- prophylactic
- vegetable juice
- foodstuff
- Prior art date
Links
- 230000000069 prophylactic effect Effects 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 10
- 230000001225 therapeutic effect Effects 0.000 title claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 229930003231 vitamin Natural products 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 235000015203 fruit juice Nutrition 0.000 claims abstract description 16
- 235000015192 vegetable juice Nutrition 0.000 claims abstract description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 8
- 239000011648 beta-carotene Substances 0.000 claims abstract description 8
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 8
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 8
- 239000011718 vitamin C Substances 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- 150000002148 esters Chemical class 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 235000021323 fish oil Nutrition 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 150000001579 beta-carotenes Chemical class 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract description 8
- 238000003860 storage Methods 0.000 abstract description 8
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 8
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 abstract description 7
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 abstract description 7
- 229960002747 betacarotene Drugs 0.000 abstract description 7
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 7
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract description 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract description 4
- 239000000796 flavoring agent Substances 0.000 abstract description 3
- 235000019634 flavors Nutrition 0.000 abstract description 3
- 201000011529 cardiovascular cancer Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 14
- 238000011321 prophylaxis Methods 0.000 description 11
- 241000251468 Actinopterygii Species 0.000 description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 7
- 235000019155 vitamin A Nutrition 0.000 description 7
- 239000011719 vitamin A Substances 0.000 description 7
- 229940045997 vitamin a Drugs 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- 239000006014 omega-3 oil Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 4
- 206010067171 Regurgitation Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003026 cod liver oil Substances 0.000 description 3
- 235000012716 cod liver oil Nutrition 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 150000004492 retinoid derivatives Chemical class 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043903 Tobacco abuse Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000020627 health maintaining nutrition Nutrition 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Jellies, Jams, And Syrups (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Engine Equipment That Uses Special Cycles (AREA)
- Optical Transform (AREA)
Abstract
Description
Oppfinnelsen angår fremstilling av et næringsmiddel, som ved gjentatt inntak har profylaktisk og/eller terapeutisk virkning, til forebygging og/eller helbredelse av bestemte sykdommer, hovedsakelig sivilisasjonssykdommer, som er betinget av usunn ernæringsmåte, alkohol- og nikotinmisbruk og en tiltagende miljøbelastning, som f.eks. kardiovaskulære sykdommer, såsom hjerteinfarkt og arteriosklerose eller kreft. The invention relates to the production of a foodstuff, which, when taken repeatedly, has a prophylactic and/or therapeutic effect, for the prevention and/or healing of specific diseases, mainly diseases of civilization, which are conditioned by an unhealthy diet, alcohol and nicotine abuse and an increasing environmental burden, such as .ex. cardiovascular diseases, such as heart attack and arteriosclerosis or cancer.
Ingen betviler betydningen og viktigheten av profylakse ved forebygging av sykdommer. Likevel er inntil nå publikums oppmerksomhet, kunnskap, akseptering og virkeliggjøring, heri medregnet tilstanden til forskningen på dette område, dessverre ikke tilsvarende. Dog har det i noen land, bl.a. i Sveits, pågått flerårige forskningsprosjekter på dette område. Hos publikum, fremfor alt i industrilandene, utgjør mentalitet, bekvemmelighet og vaner betydelige hindringer. Vanligvis ligger nåtiden nærmere enn fremtiden for menneskene i disse land og tanken på mulighet eller sannsynlighet for en fremtidig alvorlig sykdom blir fortrengt. Spisevanene fører til et for stort opptak over tid av skadelige næringsmidler, som f.eks. mettede fettsyrer, henholdsvis glycerid-inneholdene fett, og kullhydrater. I tillegg kommer at mye av det apostelene for såkalt sunn ernæring anbefaler publikum er dels besværlig å tilberede, dels alt annet enn attraktivt eller velsmakende. Det er kjent at flerumettede fettsyrer, særlig flerumettede olefine omega-3-fettsyrer, som i form av sin glycerinester utgjør bestanddeler av fiskeolje og fisketran, også kjent som levertran, og etter fiskeart og fangested utgjør 20 - 33% av den totale fettmengde i fiskeolje, beskytter mot kardiovaskulære sykdommer, såsom hjerteinfarkt og arteriosklerose, og som på grunnlag av undersøkelser i senere tid kan antas og ventes å ha en profylaktisk virkning mot kreft. Undersøkelser, f.eks. over spisevanene til grønnlandseskimoer, som konsumerer store mengder fisk, bekrefter disse virkningene. I Japan, hvor fisk likeså danner en vesentlig bestanddel av ernæringen, kunne lignende funn fastslåes. En langtidsundersøkelse i Holland har vist at konsum av bare 30 g fisk pr. dag bevirket en 50% reduksjon av koronarmortalitet, sammenlignet med kontroll- personer som ikke spiste fisk. Videre kunne det i kliniske forsøk entydig bli påvist, at gjennom regelmessig inntak fiskeolje med et innhold av eicosapentaensyre og docosaheksaensyre over lenger tid ga følgende virkninger: - senking av triglycerid- og kolesterolspeilene; No one doubts the importance and importance of prophylaxis in the prevention of diseases. Nevertheless, until now the public's attention, knowledge, acceptance and realization, including the state of research in this area, is unfortunately not equivalent. However, in some countries, i.a. in Switzerland, ongoing multi-year research projects in this area. With the public, above all in the industrialized countries, mentality, convenience and habits constitute significant obstacles. Usually the present is closer than the future for the people in these countries and the thought of the possibility or probability of a future serious illness is repressed. Eating habits lead to an excessive intake over time of harmful foodstuffs, such as e.g. saturated fatty acids, respectively glyceride-containing fats, and carbohydrates. In addition, much of what the apostles of so-called healthy nutrition recommend to the public is partly difficult to prepare, partly anything but attractive or tasty. It is known that polyunsaturated fatty acids, in particular polyunsaturated olefinic omega-3 fatty acids, which in the form of their glycerin esters are components of fish oil and fish oil, also known as cod liver oil, and depending on the species of fish and place of capture make up 20 - 33% of the total amount of fat in fish oil , protects against cardiovascular diseases, such as heart attacks and arteriosclerosis, and which, on the basis of recent research, can be assumed and is expected to have a prophylactic effect against cancer. Surveys, e.g. of the eating habits of Greenland Eskimos, who consume large quantities of fish, confirms these effects. In Japan, where fish also forms an important part of the diet, similar findings could be established. A long-term study in Holland has shown that consumption of just 30 g of fish per day resulted in a 50% reduction in coronary mortality, compared to control subjects who did not eat fish. Furthermore, it could be unequivocally demonstrated in clinical trials that through regular intake of fish oil with a content of eicosapentaenoic acid and docosahexaenoic acid over a longer period of time produced the following effects: - lowering of triglyceride and cholesterol levels;
forbedring av blodets strømningsegenskaper; improvement of blood flow properties;
nedsetting av trombosyttaggregering (blodstørkning); reduction of platelet aggregation (blood clotting);
senking av blodgjennomstrømningsmotstanden. lowering blood flow resistance.
På tross av disse kjente, fordelaktige virkningene av fiskeolje og dets innholdsstoffer er etterspørselen etter disse produkter overordentlig liten, som uten tvil kan føres tilbake til den ubehagelige smak av fiskeolje, fisketran, såsom levertran. I denne sammenheng skal det huskes at i tidligere tider ble unge mennesker, fra spebarnsalder til ungdomstiden, tvunget til daglig å svelge 2-3 kaffeskjeer med levertran. Personer, som enda lever, husker i dag med grøss denne prosedyre som de måtte finne seg i. Levertran ble i sin tid ansett som et universal-middel mot dårlig ernæringstilstand, skrofulose, kroniske infeksjoner, keratomalacia, vekst- og utviklingsforstyrrelser, såvel som mot mangeltilstander i svangerskapet pga. sin kaloririkdom, sin lette absorberbarhet og sitt høye vitamininnhold. Derimot fikk i sin tid de kardiovaskulære virkningene ingen oppmerksomhet. På grunn av den nyere tids viten er nå de kardiovaskulære virkninger og den med sikkerhet forventede profylaktiske virkning mot kreft rykket i forgrunnen. Tross dette motvirker riktignok den ubehagelige smaken til fiskeolje, henholdsvis fisketran et "frivillig", regelmessig inntak, en smak som også fremkaller ubehagelige oppstøt hos konsumenten etter inntak. I tillegg kan det anføres at de angjeldende virksomme omega-3-fettsyrer i ren form, f.eks. fremstilt gjennom ekstraksjon, for øyeblikket ikke står til rådighet i tilstrekkelig mengde og til fornuftige priser. For å motvirke abstinensen, betinget av den ubehagelige smak, er i senere tid fiskeolje blitt tilbudt i kapsler gjennom apotekene. Dette førte, ved siden av høy pris, til en underdosering, da innholdet i en enkel kapsel er alt for lite til å fremkalle de ønskede profylaktiske og/eller terapeutiske virkninger; inntaket av et flertall av slike kapsler finnes imidlertid av mange ikke tilrådelig, samtidig som ubehagelige oppstøt i tillegg ikke utelukkes. Despite these well-known, beneficial effects of fish oil and its ingredients, the demand for these products is extremely small, which can no doubt be traced back to the unpleasant taste of fish oil, fish oil, such as cod liver oil. In this context, it should be remembered that in earlier times, young people, from infancy to adolescence, were forced to swallow 2-3 coffee spoons of cod liver oil daily. People who are still alive today remember with shudder this procedure that they had to go through. deficiency conditions in pregnancy due to its caloric richness, its easy absorbability and its high vitamin content. In contrast, at the time the cardiovascular effects received no attention. Due to recent knowledge, the cardiovascular effects and the reliably expected prophylactic effect against cancer have now come to the fore. Despite this, it is true that the unpleasant taste of fish oil, respectively fish oil, counteracts "voluntary", regular consumption, a taste that also causes unpleasant regurgitation in the consumer after consumption. In addition, it can be stated that the active omega-3 fatty acids in question in pure form, e.g. produced through extraction, is currently not available in sufficient quantity and at reasonable prices. In order to counteract withdrawal, due to the unpleasant taste, fish oil has recently been offered in capsules through pharmacies. This led, in addition to the high price, to an underdosage, as the content of a single capsule is far too small to elicit the desired prophylactic and/or therapeutic effects; however, the intake of a majority of such capsules is considered by many to be inadvisable, while unpleasant regurgitation is also not excluded.
Undersøkelser har videre vist at flerumettede olefine fettsyrer også fremviser en profylaktisk anti-kreftvirkning. Vesentlig kjent og stadfestet gjennom undersøkelser er imidlertid det faktum at kreftrisikoen kan reduseres gjennom bestemte vitaminer, såsom vitamin E, vitamin A, særlig dennes forløper beta-karotin, og vitamin A±(retinol) såvel som vitamin C. Disse vitaminer fremstiller følgelig virksomme hjelpemidler for kreftprofylaksen og kreftterapien. Riktignok må det fastholdes at virkningen til de enkelte vitaminer, alt etter helbredelse, patologi og stedet for opptreden av forskjellige krefttyper, er forskjellig, og et enkelt vitamin i regelen bare viser den ønskede virkning for en bestemt type av kreft. Studies have also shown that polyunsaturated olefinic fatty acids also exhibit a prophylactic anti-cancer effect. Essentially known and confirmed through research, however, is the fact that the cancer risk can be reduced through certain vitamins, such as vitamin E, vitamin A, especially its precursor beta-carotene, and vitamin A± (retinol) as well as vitamin C. These vitamins consequently produce effective aids for cancer prophylaxis and cancer therapy. Admittedly, it must be maintained that the effect of the individual vitamins, depending on the healing, pathology and location of the appearance of different types of cancer, is different, and a single vitamin as a rule only shows the desired effect for a specific type of cancer.
Hensikten med oppfinnelsen er derfor å tilveiebringe en fremgangsmåte til fremstilling av et næringsmiddel av den i begynnelsen omtalte art, som er fri for de i det foregående omtalte ulemper, og såvel smaksmessig som også i prismessig henseende er behagelig og aktraktiv, ikke utviser ubehagelig lukt, er sunnhetsfremmende og lett og bekvem å ta inn, og garanterer en tilstrekkelig høy dosering. The purpose of the invention is therefore to provide a method for the production of a foodstuff of the type mentioned at the beginning, which is free from the previously mentioned disadvantages, and both in terms of taste and also in terms of price is pleasant and attractive, does not exhibit an unpleasant smell, is health-promoting and easy and convenient to take, and guarantees a sufficiently high dosage.
Den oppstilte oppgave blir løst gjennom fremgangsmåten til fremstilling av næringsmiddelet i henhold til oppfinnelsen, som inneholder minst en kombinasjon av de følgende bestanddeler: A) minst en profylaktisk og/eller terapeutisk virkende flerumettet omega-3-fettsyre, og/eller dens ester; og B) en eller flere vitaminer og/eller provitaminer, med den samme eller ytterligere profylaktisk eller terapeutisk virkning. The stated task is solved through the method for producing the food product according to the invention, which contains at least one combination of the following ingredients: A) at least one prophylactically and/or therapeutically effective polyunsaturated omega-3 fatty acid, and/or its ester; and B) one or more vitamins and/or provitamins, with the same or additional prophylactic or therapeutic effect.
Næringsmiddelet som er fremstilt i henhold til oppfinnelsen foreligger fortrinnsvis i form av en frukt- og/eller grønnsaks-saft eller en med disse tilberedt drikke, og utmerker seg gjennom behagelig smak og lukt; den kan dermed konsumeres lett og uten motvilje. Egensmaken til de flerumettede omega-3-fettsyrer som utgjør komponent A, blir skjult av de øvrige bestanddeler i næringsmiddelet, eller blir undertrykket gjennom vekselvirkning mellom komponentene A og B, særlig den gjen-sidige stabilisering, som vil bli behandlet nærmere i det følgende, slik at den overhodet ikke trer frem. The food produced according to the invention is preferably in the form of a fruit and/or vegetable juice or a drink prepared with these, and is characterized by a pleasant taste and smell; it can thus be consumed easily and without reluctance. The characteristic taste of the polyunsaturated omega-3 fatty acids that make up component A is hidden by the other ingredients in the foodstuff, or is suppressed through interaction between components A and B, in particular the mutual stabilization, which will be dealt with in more detail in the following, so that it does not appear at all.
Komponentene A og B foreligger hensiktsmessig i sykdomspro-fylaktiske og/eller sykdomsterapeutiske mengder. Disse kan varieres og kan om ønskelig bestemmes i henhold til næringstil-budet i regionen hvor næringsmiddelet blir tilbudt for konsum. Således kan f.eks. i en region, hvor mye fisk blir fortært, andelen av komponent A nedsettes og omvendt, forhøyes i en region hvor lite fisk blir fortært. Dessuten kan vitamin-tilbudet variere og tilpasses levebetingelsene slik at opptreden av stedsspesifikke mangelfenomener kan virkningsfullt forhindres. Components A and B are suitably present in disease prophylactic and/or disease therapeutic amounts. These can be varied and, if desired, can be determined according to the food supply in the region where the food is offered for consumption. Thus, e.g. in a region where a lot of fish is consumed, the proportion of component A is reduced and, conversely, increased in a region where little fish is consumed. In addition, the vitamin supply can vary and be adapted to living conditions so that the appearance of site-specific deficiency phenomena can be effectively prevented.
Næringsmiddelet fremstilt i henhold til oppfinnelsen blir som regel tilbudt i emballert form, f.eks. i små flasker hvor hver pakning fordelaktig inneholder en dagsdosering av komponentene A og B. Disse kan konsumeres porsjonsvis, f.eks. i to til fire porsjoner, hvorved den leilighetsvise konsumering av større mengder ikke gir skadelig virkning. The food produced according to the invention is usually offered in packaged form, e.g. in small bottles where each pack advantageously contains a daily dosage of components A and B. These can be consumed in portions, e.g. in two to four portions, whereby the occasional consumption of larger quantities does not produce harmful effects.
Næringsmiddelet fremstilt i henhold til oppfinnelsen inneholder, som komponent A-dannende flerumettede omega-3-fettsyrer, fortrinnsvis eicosapentaensyre og/eller docosaheksaensyre eller deres estere, f.eks. som bestanddel av fiskeolje. Innholdet av de nevnte syrer utgjør, alt etter fiskeart og område som fisken har levet i, 20 - 33%, beregnet ut fra den samlede fettmengde i fiskeoljen. De nevnte syrer kan imidlertid også foreligge i ren form, så lenge de rene syrer er disponible i tilstrekkelige mengder og til en rimelig pris. The food produced according to the invention contains, as component A-forming polyunsaturated omega-3 fatty acids, preferably eicosapentaenoic acid and/or docosahexaenoic acid or their esters, e.g. as a component of fish oil. The content of the aforementioned acids amounts, depending on the species of fish and the area in which the fish has lived, to 20 - 33%, calculated from the total amount of fat in the fish oil. However, the mentioned acids can also be present in pure form, as long as the pure acids are available in sufficient quantities and at a reasonable price.
Som komponent B inneholder næringsmiddelet fremstilt i henhold til oppfinnelsen fortrinnsvis vitamin A eller dennes forløper, beta-karotin, vitamin C, vitamin E og/eller retinoid. De nevnte vitaminer og provitaminer kan fullstendig eller delvis, særlig i tilfelle av frukt- eller grønnsakssafter, inneholdes i saften eller saftblandingen som danner grunnlaget og eventuelt bare bli supplert. Fortrinnsvis blir de imidlertid tilsatt saft-eller saftblandingsgrunnlaget, for å kunne oppnå en tilstrekkelig høy dosering. Da det i tilfelle av vitamin A kan forekomme uønskede og eventuelle skadelige bivirkninger ved overdosering, inneholder næringsmiddelet, istedenfor vitamin A, fortrinnsvis forløperen beta-karotin, som blir overført av kroppen til den nødvendige mengde vitamin A, mens resten går til utskillelse. Retinoidene dreier seg om nære slektninger av vitamin A med vesentlig den samme virkning. Fremstilling av retinoid er i gang, hvor målet er å få retinoid som muligens viser få bivirkninger. As component B, the nutritional product prepared according to the invention preferably contains vitamin A or its precursor, beta-carotene, vitamin C, vitamin E and/or retinoid. The aforementioned vitamins and provitamins can be completely or partially, especially in the case of fruit or vegetable juices, contained in the juice or juice mixture that forms the basis and possibly only be supplemented. Preferably, however, they are added to the juice or juice mixture base, in order to achieve a sufficiently high dosage. Since, in the case of vitamin A, unwanted and potentially harmful side effects can occur in the event of an overdose, the food, instead of vitamin A, preferably contains the precursor beta-carotene, which is transferred by the body to the required amount of vitamin A, while the rest is excreted. The retinoids are close relatives of vitamin A with essentially the same effect. The production of retinoid is underway, where the goal is to obtain a retinoid that possibly shows few side effects.
Komponent B utfyller på effektiv måte komponent A ved profylakse av kardiovaskulære sykdommer, og er dessuten særlig av betydning ved kreftprofylakse. Dette er desto viktigere siden mengden av komponent A, som inneholdes i næringsmiddelet av ovennevnte type, ikke er tilstrekkelig for en effektiv kreftprofylakse, men ikke uten videre kan økes etter ønske. Component B effectively complements component A in the prophylaxis of cardiovascular diseases, and is also particularly important in cancer prophylaxis. This is all the more important since the amount of component A, which is contained in the foodstuff of the above type, is not sufficient for an effective cancer prophylaxis, but cannot easily be increased as desired.
Ved siden av komponent A og B inneholder næringsmiddelet fortrinnsvis sukker, søt- og/eller smaks- eller aromastoffer i tillegg. De siste tjener til å dekke over den ubehagelige egen-smak, henholdsvis egenlukt til omega-3-fettsyrer, som i regelen tilsettes i form av fiskeolje, de gir næringsmiddelet en, også for følsomme ganer og neser, behagelig smak. Et innhold av smaks- og/eller aromastoffer er særlig å anbefale når smaks-intensiteten til de øvrige bestanddeler, som er kombinert med fiskeolje, er for svak til å dekke over fiskeoljesmaken. Utval-get av egnede smaks- eller aromastoffer er kjent for en fagmann på området og kan foretas ved hjelp av faglitteratur og tabellverker, hvorved som regel naturprodukter er foretrukket. In addition to components A and B, the foodstuff preferably contains sugar, sweet and/or flavoring or aroma substances in addition. The latter serve to cover up the unpleasant aftertaste or smell of omega-3 fatty acids, which are usually added in the form of fish oil, they give the food a pleasant taste, also for sensitive palates and noses. A content of flavoring and/or aroma substances is particularly recommended when the flavor intensity of the other ingredients, which are combined with fish oil, is too weak to cover the fish oil taste. The selection of suitable flavoring or aroma substances is known to a person skilled in the field and can be made with the help of specialist literature and tables, whereby natural products are usually preferred.
Utover dette kan næringsmiddelet inneholde enda ytterligere profylaktisk eller terapeutisk virkende tilsettinger, f.eks. vitamin D, for å avhjelpe mangler som opptrer i området der næringsmiddelet skal konsumeres. In addition to this, the nutritional product may contain even further prophylactically or therapeutically effective additions, e.g. vitamin D, to remedy deficiencies that occur in the area where the food is to be consumed.
Dersom næringsmiddelet foreligger i form av en frukt- og/eller grønnsakssaft inneholder det hensiktsmessige viskositetsfor-høyende tilsetninger til forbedring av lagringsstabilitet, spesielt til forhindring av en uønsket separasjon av safter eller saftblandinger som foreligger som emulsjon, og som fører til forringet utseende, likesom til forhøyelse av oksidasjons-stabiliteten. Som viskositetsforhøyende tilsetning kommer f.eks. fruktsaftkonsentrater og pektin i betraktning. If the food is in the form of a fruit and/or vegetable juice, it contains appropriate viscosity-increasing additives to improve storage stability, in particular to prevent an unwanted separation of juices or juice mixtures that are present as an emulsion, and which lead to a deteriorated appearance, as well as to increase in oxidation stability. As a viscosity-increasing additive comes e.g. fruit juice concentrates and pectin into consideration.
Til forbedring av lagringsstabiliteten, spesielt stabiliteten ovenfor oksiderende innflytelse, og fremfor alt når næringsmiddelet skal tilbys i sterilisert form, anbefales et innhold av antioksiderende midler. To improve the storage stability, especially the stability against oxidizing influence, and above all when the food is to be offered in sterilized form, a content of antioxidants is recommended.
Som allerede omtalt bør pakningsstørrelsen, når næringsmiddelet foreligger i emballert form, være således avpasset at hver enkelt pakning, f.eks. en flaske i tilfelle av en drikk basert på frukt- og/eller grønnsakssaft, inneholder en dagsdose av komponent A og B, hvorved dagsporsjonen f.eks. beløper seg til 1/3 1. saft, saftblanding eller av disse fremstilte drikke. As already mentioned, the package size, when the foodstuff is available in packaged form, should be adjusted so that each individual package, e.g. a bottle in the case of a drink based on fruit and/or vegetable juice, contains a daily dose of components A and B, whereby the daily portion e.g. amounts to 1/3 1. juice, juice mixture or drinks made from these.
I en foretrukket fruktsaftdrikk utviser en dagsporsjon på 1/3 1 følgende sammensetning: In a preferred fruit juice drink, a daily portion of 1/3 1 exhibits the following composition:
En ytterligere foretrukket drikk basert på frukt- og/eller grønnsakssaft inneholder i 525 g ferdig drikk: A further preferred drink based on fruit and/or vegetable juice contains in 525 g of finished drink:
Fremstillingsfremgangsmåten for næringsmiddelet i henhold til oppfinnelsen blir nedenfor beskrevet; for eksempel ved fremstilling av en drikk basert på en frukt- og/eller grønnsaks-saft. Gjennomføring av fremgangsmåten foregår således ved at; a) fettsyrene og/eller deres estere, eller fiskeolje som inneholder disse, stilles til disposisjon i form av et The manufacturing process for the food product according to the invention is described below; for example when making a drink based on a fruit and/or vegetable juice. Implementation of the procedure thus takes place by: a) the fatty acids and/or their esters, or fish oil containing these, are made available in the form of a
tørt pulver; dry powder;
b) vitamin E og en delmengde eller hele mengden av beta-karotin i form av et tørt pulver tilsettes og denne b) vitamin E and a partial amount or the entire amount of beta-carotene in the form of a dry powder is added and this
blanding blandes med vitamin C, som foreligger i tørket mixture is mixed with vitamin C, which is available in dried form
form; shape;
c) den tørre blanding, som ble oppnådd i trinn b), innrøres i frukt- og/eller grønnsakssaft som er oppvarmet til minst c) the dry mixture obtained in step b) is stirred into fruit and/or vegetable juice that has been heated to at least
40°C, eller innrøres først i vann, oppvarmet til minst 40°C, og settes der sammen med den oppvarmede og til-beredte frukt- og/eller grønnsakssaft med samme temperatur, hvorved mengden av frukt- og/eller grønnsakssaft 40°C, or first stirred into water, heated to at least 40°C, and put there together with the heated and prepared fruit and/or vegetable juice at the same temperature, whereby the amount of fruit and/or vegetable juice
utgjør mer enn 60% av endeproduktet; og make up more than 60% of the final product; and
d) den oppnådde blanding oppfylles til 100% med vann og tappes over på beholdere for transport og/eller salg. d) the obtained mixture is filled to 100% with water and poured into containers for transport and/or sale.
Med denne fremgangsmåte er det vesentlig at de fettløselige komponenter, i trinn a) fettsyrene og/eller deres estere, eller fiskeolje som inneholder disse, og i trinn b), vitamin E og beta-karotin, blir tilsatt i form av et tørt pulver. Fiskeolje i form av et tørt pulver er kommersielt oppnåelig og består av fiskeolje, gelatin, rørsukker, askorbat, tokoferol og trikalsiumfosfat. 25% av produktet er ren fiskeolje, som igjen er sammensatt av 18% eicosapentaensyre og 12% dokosaheksaen-syre. På denne måte kan ulemper, som skriver seg fra de forskjellige løsningsforhold til de enkelte komponenter, bli unngått. Det er kjent at enkelte av komponentene som danner drikken er vannløselige, f.eks. vitamin C, andre er bare blandbare med vann og en del fettløselig. Denne omstendighet fører til at komponentene i drikken ikke uten videre fordeler seg likt og de fettløselige komponenter svømmer, ved henstand, oppå drikken i form av oljepytter. Derved blir drikkens utseende sterkt forringet, og dette kan føre til avvisning hos konsumentene. Anvendelse av oppløsningsmidler og/eller dispergerings- eller emulgeringsmidler fører som regel bare til kortvarige resultater og er ikke ufarlige i forbindelse med næringsmidler. Tilsetting av fettløselige komponenter i tørr form gir derimot muligheten av å fremstille en drikk, hvor de nevnte ulemper ikke opptrer, og som bevarer sin homogenitet og sitt tiltalende utseende ved lengre tids lagring, f.eks.9-12 måneder. Videre kan det på denne måte oppnås at egenlukten og egensmaken til fiskeoljen, eller den flerumettede omega-3-fettsyren, i den ferdige drikk ikke, eller bare i liten grad, er merkbar, i tillegg til at senere ubehagelige oppstøt unngås. Ved fremstilling av drikken blir fortrinnsvis frukt- eller grønnsakssaft anvendt i en mengde som hensiktsmessig tilsvarer mer enn 60% av den totale mengde endeprodukt. Frukt- eller grønnsakssaften kan ytterligere tilsettes viskositetsforhøyende middel, f.eks. før innrøring av det pulverformede materiale i trinn b). Valget av det anvendte viskositetforhøyende middel ligger i hvert tilfelle innenfor fagmannens kunnskaper. I dette stadium kan også sukker, søt-, smaks- eller aromastoffer bli tilblandet, så langt dette er ønskelig. Tilsettingen av sukker kan gi en ytterligere lett forhøyelse av viskositeten, hvorigjennom risikoen for en begynnende oksidasjon av bestand-delene i drikken kan forhindres før oppløsningslikevekten innstilles. Dette skjer fordi stigende viskositet senker bevegeligheten av molekylene i saften eller saftblandingen og derved hemmer oksidasjonsreaksjonen, såvel i fremstillings-stadiet som under senere lagring av drikken. Da tap gjennom oksidasjon i størrelsesorden på 10% ikke kan unngås under fremstillingen og påfyllingsfasen, er det tilrådelig å ta hensyn til disse tap ved tilmåling av de enkelte komponenters mengder. With this method, it is essential that the fat-soluble components, in step a) the fatty acids and/or their esters, or fish oil containing these, and in step b), vitamin E and beta-carotene, are added in the form of a dry powder. Fish oil in the form of a dry powder is commercially available and consists of fish oil, gelatin, cane sugar, ascorbate, tocopherol and tricalcium phosphate. 25% of the product is pure fish oil, which in turn is composed of 18% eicosapentaenoic acid and 12% docosahexaenoic acid. In this way, disadvantages arising from the different solution conditions for the individual components can be avoided. It is known that some of the components that make up the drink are water-soluble, e.g. vitamin C, others are only miscible with water and some are fat-soluble. This circumstance means that the components in the drink are not readily distributed equally and the fat-soluble components float, in the event of a delay, on top of the drink in the form of puddles of oil. Thereby, the drink's appearance is greatly deteriorated, and this can lead to rejection by consumers. The use of solvents and/or dispersants or emulsifiers usually only leads to short-term results and is not harmless in connection with foodstuffs. The addition of fat-soluble components in dry form, on the other hand, gives the possibility of producing a drink in which the aforementioned disadvantages do not occur, and which preserves its homogeneity and its appealing appearance during longer storage, e.g. 9-12 months. Furthermore, it can be achieved in this way that the characteristic smell and taste of the fish oil, or the polyunsaturated omega-3 fatty acid, in the finished drink is not, or only to a small extent, noticeable, in addition to avoiding later unpleasant regurgitation. When producing the drink, fruit or vegetable juice is preferably used in an amount that appropriately corresponds to more than 60% of the total amount of end product. A viscosity-increasing agent can be added to the fruit or vegetable juice, e.g. before stirring in the powdered material in step b). The choice of the viscosity-increasing agent used is, in each case, within the knowledge of the person skilled in the art. At this stage, sugar, sweeteners, flavors or aromas can also be mixed in, as far as this is desired. The addition of sugar can give a further slight increase in viscosity, through which the risk of an incipient oxidation of the constituent parts in the drink can be prevented before the dissolution equilibrium is set. This happens because rising viscosity lowers the mobility of the molecules in the juice or juice mixture and thereby inhibits the oxidation reaction, both in the production stage and during later storage of the drink. As losses through oxidation in the order of 10% cannot be avoided during the manufacturing and filling phase, it is advisable to take these losses into account when measuring the quantities of the individual components.
En høyere andel av saft i den ferdige drikk, f.eks. mer enn 60%, har også et annet positivt aspekt: det sikrer en blivende uklarhetsstabilitet også ved relative høye andeler av fiskeolje, f.eks. 750 mg på 1/3 1, tilsvarende den foregående angitte oppskrift. Undersøkelser har vist at drikke med en mindre saftandel, men med like høy andel av fiskeolje, ikke viser tilfredsstillende uklarhetsstabilitet over tid. Det er antatt at ved egnet justering av andelene i komponent A og B oppnås en likevektsinnstilling, hvorigjennom uklarhetsstabiliteten blir sikret over tid. Uklarhetsstabiliteten bidrar endelig til et tiltalende utseende av drikken og dermed til at den aksepteres av konsumentene. A higher proportion of juice in the finished drink, e.g. more than 60%, also has another positive aspect: it ensures permanent turbidity stability even with relatively high proportions of fish oil, e.g. 750 mg in 1/3 1, corresponding to the previously indicated recipe. Investigations have shown that drinks with a smaller proportion of juice, but with an equally high proportion of fish oil, do not show satisfactory turbidity stability over time. It is assumed that by suitable adjustment of the proportions in components A and B, an equilibrium setting is achieved, through which the stability of opacity is ensured over time. The turbidity stability finally contributes to an appealing appearance of the drink and thus to its acceptance by consumers.
Det samme mål tjener tilsetting av små mengder av anti-oksidanter. Tilsetting av anti-oksideringsmiddel til saft eller saftblanding kan foretas samtidig med tilsetting av andre komponenter, eller umiddelbart etter. Den ferdige blanding kan umiddelbart deretter, eller før påfylling, bli sterilisert. Videre er det tilrådelig å homogenisere drikken før påfylling, da uklarhetsstabiliteten og dermed dets utseende på denne måte blir gunstig påvirket. Hvis drikken om mulig blir beskyttet mot lysets innvirkning frem til bruken, vil også dette bidra til forhøyelse av lagringsstabiliteten. The same goal is served by the addition of small amounts of anti-oxidants. Addition of anti-oxidant to juice or juice mixture can be done at the same time as the addition of other components, or immediately after. The finished mixture can be sterilized immediately afterwards, or before filling. Furthermore, it is advisable to homogenize the drink before filling, as the turbidity stability and thus its appearance is thus favorably affected. If possible, if the drink is protected from the effects of light until use, this will also contribute to increasing the storage stability.
Det var på grunn av de kjente egenskaper til komponent A og B absolutt ikke å vente at deres kombinasjon og gjensidig justering ville føre til et næringsmiddel hvis egenskaper, hva angår stabilitet ovenfor oksiderende innflytelse, uklarhetsstabilitet over tid, lagringsstabilitet, vitamininnhold, utseende, smak og luft er forbedret over disse egenskaper hos de enkelte komponenter, i en grad som langt overgår summen av egenskapene til den gitte masse av enkelkomponentene, og bare kan forklares gjennom en synergistisk samvirkning. Dokumentasjon på en slik synergistisk virkning på langtids-stabilitet er senere tilveiebragt ved Etsuo Niki; "Interaction among vitamin C, vitamin E and B-carotene", Am.J.Clin.Nutr. 1995: 62 (Suppl), side 1322S-1326S. Den fordelaktige forbedring kan ikke minst føres tilbake til at det gjennom kombinasjon av enkeltkomponentene inntrer en gjensidig beskyttende virkning. Således er det f.eks. påfallende at vitamininnholdet i kombinasjonen, bortsett fra et lite tap i begynnelsen av fremstillingsfasen, også forblir uforandret ved lengre tids lagring, f.eks. fra 9-12 måneder. Dette kunne slett ikke forventes da det er kjent, hos frukt og grønnsaker, at vitamininnholdet på grunn av nedbyggingsreaksjoner som regel allerede kort tid etter innhøsting hurtig avtar, og allerede etter forholdsvis kort tid går mot null. Det kan antas at de enkelte komponenter gjensidig stabiliseres, hvorved beta-karotin og vitamin C åpenbart har en spesiell betydning. Due to the known properties of components A and B, it was certainly not to be expected that their combination and mutual adjustment would lead to a food product whose properties, in terms of stability against oxidizing influence, turbidity stability over time, storage stability, vitamin content, appearance, taste and air is improved over these properties of the individual components, to an extent that far exceeds the sum of the properties of the given mass of the individual components, and can only be explained through a synergistic interaction. Documentation of such a synergistic effect on long-term stability was later provided by Etsuo Niki; "Interaction among vitamin C, vitamin E and B-carotene", Am.J.Clin.Nutr. 1995: 62 (Suppl), pages 1322S-1326S. The beneficial improvement can not least be traced back to the fact that a mutual protective effect occurs through the combination of the individual components. Thus, it is e.g. striking that the vitamin content of the combination, apart from a small loss at the beginning of the manufacturing phase, also remains unchanged during longer storage, e.g. from 9-12 months. This could not be expected at all, as it is known, in fruit and vegetables, that the vitamin content due to breakdown reactions usually rapidly decreases shortly after harvesting, and already after a relatively short time goes towards zero. It can be assumed that the individual components are mutually stabilised, whereby beta-carotene and vitamin C obviously have a special significance.
Langt mere betydningsfull og spesielt fremhevet er likevel den omstendighet at den fysiologiske virkning til komponent A og B utfyller hverandre på en synergistisk måte, slik at det oppnås, gjennom næringsmiddelet i henhold til oppfinnelsen, en profylaktisk og/eller terapeutisk virkning, som er vesentlig større enn den virkning som kan ventes pga. enkelt-komponentenes egne virkninger. Denne synergistiske virkning er understøttet av V. Ernst og K. Schmidt<M>0mega-3-Fettsauren plus Antioxidantzien bei Psoriasis vulgaris" Vitaminspur 9, 130-135 Far more significant and particularly emphasized is the fact that the physiological effects of components A and B complement each other in a synergistic way, so that a prophylactic and/or therapeutic effect is achieved, which is significantly greater, through the nutritional product according to the invention than the effect that can be expected due to the individual components' own effects. This synergistic effect is supported by V. Ernst and K. Schmidt<M>0mega-3-Fettsauren plus Antioxidantzien bei Psoriasis vulgaris" Vitaminspur 9, 130-135
(1994). Ytterligere bevirker kombinasjonseffekten en overordentlig spredning av virknings- og anvendelsesspekteret, særlig i sammenheng med anvendelse til profylakse og terapi av kardiovaskulære sykdommer, såvel som til kreftprofylakse og kreftterapi. Et bredt virknings- og anvendelsesspektrum er imidlertid en bestemmende forutsetning for en profylakse og/eller terapi med godt resultat pga. kompleksiteten til de nevnte sykdommer, som omfatter et flertall av lokale og patologisk forskjellige sykdommer. Nettopp i tilfelle av kreft bør det ikke bli oversett at de forskjellige typer av kreft ikke bare adskilles ved sin lokalisering, men også gjennom tilfriskning og patologi. En virksom kreftprofylakse kan derfor bare oppnås gjennom en samvirkning av flere komponenter, som utfyller og gjensidig potensierer hverandre. Dette er tilfelle ved næringsmiddelet i henhold til oppfinnelsen pga. den observerte og utvilsomt eksisterende synergisme. Ved inntak av et enkelt vitamin, eller en umettet omega-3-fettsyre, blir som regel bare en meget begrenset virkning oppnådd. De enkelte virksomme stoffkomponenter utfolder sin virkning alene eller bare i et meget begrenset område, f.eks. bare ved et spesi-fisert sykdomsbilde, mens ved et annet lignende sykdomsbilde er de nesten ikke, eller slett ikke virksomme. Dette er særlig uheldig i tilfelle av kreftprofylakse og kreftterapi fordi det nettopp hos disse sykdommer er en betydelig forskjell hva angår egenart, stedet hvor de opptrer, tilfriskning og patologi. Det var derfor overordentlig overraskende, og slett ikke forutsig-bart, at det kunne bli fremskaffet et profylaktisk og/eller terapeutisk virkende næringsmiddel med et så bredt anvendelses-og virkningsspektrum, ved kombinasjon av komponentene A og B, såvel som gjennom utvalg og kombinasjon av ingredienser, som dannes av disse komponenter, og som danner et vesentlig kjennetegn ved den foreliggende oppfinnelse. (1994). Furthermore, the combination effect causes an extraordinary spread of the spectrum of action and application, particularly in connection with application for the prophylaxis and therapy of cardiovascular diseases, as well as for cancer prophylaxis and cancer therapy. However, a broad spectrum of effects and applications is a decisive prerequisite for a prophylaxis and/or therapy with good results due to the complexity of the aforementioned diseases, which include a majority of local and pathologically different diseases. Precisely in the case of cancer, it should not be overlooked that the different types of cancer are not only distinguished by their location, but also through recovery and pathology. Effective cancer prophylaxis can therefore only be achieved through the interaction of several components, which complement and mutually potentiate each other. This is the case with the food product according to the invention because the observed and undoubtedly existing synergism. When taking a single vitamin, or an unsaturated omega-3 fatty acid, usually only a very limited effect is achieved. The individual active substance components exert their effect alone or only in a very limited area, e.g. only in the case of a specified disease picture, while in another similar disease picture they are hardly, or not at all, effective. This is particularly unfortunate in the case of cancer prophylaxis and cancer therapy because precisely in these diseases there is a significant difference in terms of characteristics, the place where they occur, recovery and pathology. It was therefore extremely surprising, and not at all predictable, that a prophylactic and/or therapeutically active food product with such a broad spectrum of application and effect could be obtained, by combining components A and B, as well as through selection and combination of ingredients, which are formed by these components, and which form an essential characteristic of the present invention.
På denne måte blir det entydig åpnet muligheten for å tilfore kroppen tilstrekkelige mengder av de virksomme stoffer, som er nødvendig for en effektiv profylakse, nemlig umettede omega-3-fettsyrer på den ene side og vitaminer på den andre side, på behagelig måte uten frykt for å fremskaffe uønskede bivirkninger. In this way, the possibility of supplying the body with sufficient amounts of the active substances, which are necessary for an effective prophylaxis, namely unsaturated omega-3 fatty acids on the one hand and vitamins on the other hand, in a comfortable way without fear to produce unwanted side effects.
Claims (5)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH174590 | 1990-05-22 | ||
CH178390 | 1990-05-25 | ||
CH178490 | 1990-05-25 | ||
PCT/CH1991/000120 WO1991017670A1 (en) | 1990-05-22 | 1991-05-21 | Foodstuff with prophylactic and/or curative effect and process for making it |
Publications (4)
Publication Number | Publication Date |
---|---|
NO920260D0 NO920260D0 (en) | 1992-01-20 |
NO920260L NO920260L (en) | 1992-01-20 |
NO180148B true NO180148B (en) | 1996-11-18 |
NO180148C NO180148C (en) | 1997-02-26 |
Family
ID=27173215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO920260A NO180148C (en) | 1990-05-22 | 1992-01-20 | Process for the preparation of foodstuffs which have a prophylactic and / or therapeutic effect upon repeated intake |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0484486B1 (en) |
JP (1) | JPH05500162A (en) |
KR (1) | KR920702935A (en) |
AT (1) | ATE133318T1 (en) |
AU (1) | AU651975B2 (en) |
CA (1) | CA2064025A1 (en) |
DE (1) | DE59107305D1 (en) |
DK (1) | DK0484486T3 (en) |
ES (1) | ES2085473T3 (en) |
FI (1) | FI920258A0 (en) |
GR (1) | GR3019747T3 (en) |
NO (1) | NO180148C (en) |
WO (1) | WO1991017670A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041324B2 (en) | 1999-12-28 | 2006-05-09 | Pronova Biocare As | Drinkable omega-3 preparation and storage stabilization |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE41029E1 (en) | 1990-03-13 | 2009-12-01 | The Regents Of The University Of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US6083220A (en) | 1990-03-13 | 2000-07-04 | The Regents Of The University Of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
USRE42625E1 (en) | 1990-03-13 | 2011-08-16 | The Regents Of The University Of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
DE4304394A1 (en) * | 1993-02-13 | 1993-09-02 | Fresenius Ag | Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins |
CA2119000A1 (en) * | 1993-03-19 | 1994-09-20 | David Frederick Horrobin | Formulation for use in smokers |
EP0713368B1 (en) * | 1993-08-14 | 1998-03-18 | Eckes Aktiengesellschaft | Storage stable, enriched liquid foodstuff and process for producing the same |
JPH07107938A (en) * | 1993-10-08 | 1995-04-25 | Sanei Gen F F I Inc | Food containing docosahexaenoic acid oil |
JP3407083B2 (en) * | 1994-04-04 | 2003-05-19 | 株式会社ベルリッチ | Bread manufacturing method |
FR2723315B1 (en) * | 1994-08-02 | 1996-10-25 | Cird Galderma | METHOD AND COMPOSITION FOR STIMULATING DIFFERENTIATION OF PREADIPOCYTE CELLS AND RELATED THERAPEUTIC TREATMENTS |
GB9423625D0 (en) * | 1994-11-23 | 1995-01-11 | Scotia Holdings Plc | Fortified fruit juice |
US6235331B1 (en) * | 1999-07-29 | 2001-05-22 | Nisshin Flour Milling Co Ltd | Modified fish oil type material containing highly unsaturated fatty acid and/or esters thereof, and a composition containing said material |
US6436431B1 (en) | 2001-07-02 | 2002-08-20 | Diane Wright Hoffpauer | Fortified rice bran food product and method for promoting cardiovascular health |
US7416752B2 (en) | 2004-01-06 | 2008-08-26 | Sharp Ingrained Functional Foods, Inc. | Method of fortifying seeds with an essential fatty acid, fortified seed and food product |
EP2014180A1 (en) * | 2007-07-08 | 2009-01-14 | Barilla G. e R. Fratelli S.p.A. | Composition useful for the reduction of the cardivascular risk and foods that contain it |
US20090162524A1 (en) * | 2007-12-21 | 2009-06-25 | Tropicana Products, Inc. | Food product including one or more omega-3 fatty acids and one or more fruit flavors |
US20090162525A1 (en) * | 2007-12-21 | 2009-06-25 | Tropicana Products, Inc. | Food product including one or more encapsulated omega-3 fatty acids and one or more fruit flavors |
EP2247201B1 (en) * | 2008-02-12 | 2016-11-30 | Ambo Innovation LLC | Food products containing omega-3 fatty acids |
NO20081487L (en) | 2008-03-27 | 2009-09-28 | Smartfish As | Health promoting drink |
US9445621B2 (en) * | 2009-09-04 | 2016-09-20 | Dsm Ip Assets B.V. | Juice or nectar formulations |
WO2012085671A2 (en) * | 2010-12-21 | 2012-06-28 | Omegatri As | Antioxidants in fish oil powder and tablets |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2098065A (en) * | 1981-04-14 | 1982-11-17 | Nippon Suisan Kaisha Ltd | Antithrombotic compositions containing docosahexaenoic acid |
US4479971A (en) * | 1982-11-04 | 1984-10-30 | General Foods Inc. | Glyceride fat based clouds for ready-to-drink beverages |
NO162770C (en) * | 1983-05-28 | 1990-02-14 | Sekimoto Hiroshi | PROCEDURE FOR STABILIZING A FAT ACID ESTER COMPOUND. |
US4737367A (en) * | 1985-07-26 | 1988-04-12 | Langer David W | Fruit drink with vitamins |
GB2209936A (en) * | 1987-09-18 | 1989-06-01 | Max Diener | Preparations for alleviating arthritis |
CA1331930C (en) * | 1987-11-30 | 1994-09-13 | Lisa R. Schroeder | Beverages containing fish oils stabilized with fructose |
AU620929B2 (en) * | 1988-10-27 | 1992-02-27 | Bar-Ilan University | Method and compositions for treating alzheimer's disease, related dementias and epilepsy |
-
1991
- 1991-05-21 DK DK91909332.8T patent/DK0484486T3/en not_active Application Discontinuation
- 1991-05-21 KR KR1019920700139A patent/KR920702935A/en not_active Application Discontinuation
- 1991-05-21 WO PCT/CH1991/000120 patent/WO1991017670A1/en active IP Right Grant
- 1991-05-21 AU AU77836/91A patent/AU651975B2/en not_active Ceased
- 1991-05-21 DE DE59107305T patent/DE59107305D1/en not_active Expired - Fee Related
- 1991-05-21 ES ES91909332T patent/ES2085473T3/en not_active Expired - Lifetime
- 1991-05-21 EP EP91909332A patent/EP0484486B1/en not_active Expired - Lifetime
- 1991-05-21 JP JP3508432A patent/JPH05500162A/en active Pending
- 1991-05-21 AT AT91909332T patent/ATE133318T1/en not_active IP Right Cessation
- 1991-05-21 CA CA002064025A patent/CA2064025A1/en not_active Abandoned
-
1992
- 1992-01-20 NO NO920260A patent/NO180148C/en unknown
- 1992-01-21 FI FI920258A patent/FI920258A0/en unknown
-
1996
- 1996-04-24 GR GR960401144T patent/GR3019747T3/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041324B2 (en) | 1999-12-28 | 2006-05-09 | Pronova Biocare As | Drinkable omega-3 preparation and storage stabilization |
Also Published As
Publication number | Publication date |
---|---|
DK0484486T3 (en) | 1996-06-10 |
ES2085473T3 (en) | 1996-06-01 |
NO180148C (en) | 1997-02-26 |
CA2064025A1 (en) | 1991-11-23 |
AU7783691A (en) | 1991-12-10 |
NO920260D0 (en) | 1992-01-20 |
EP0484486B1 (en) | 1996-01-24 |
JPH05500162A (en) | 1993-01-21 |
KR920702935A (en) | 1992-12-17 |
GR3019747T3 (en) | 1996-07-31 |
FI920258A0 (en) | 1992-01-21 |
AU651975B2 (en) | 1994-08-11 |
ATE133318T1 (en) | 1996-02-15 |
EP0484486A1 (en) | 1992-05-13 |
WO1991017670A1 (en) | 1991-11-28 |
NO920260L (en) | 1992-01-20 |
DE59107305D1 (en) | 1996-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO180148B (en) | Process for the preparation of foodstuffs which have a prophylactic and / or therapeutic effect upon repeated intake | |
JP7007010B2 (en) | Lipid-containing composition and its usage | |
EP1241955B1 (en) | Drinkable omega-3 preparation | |
JP4977179B2 (en) | Oil-containing food enriched with ubiquinol | |
EP3135119B1 (en) | Beverage composition for weight gain suppression | |
US8828472B2 (en) | Food products containing omega-3 fatty acids | |
US20060088574A1 (en) | Nutritional supplements | |
JP4351062B2 (en) | Food enriched with ubiquinone | |
JP2599400B2 (en) | Formulated liquid nutritional composition for glucose intolerant patients | |
US20050143459A1 (en) | Use of medium-chain triglycerides for the prevention and therapy of adiposity | |
US20150173410A1 (en) | Beverage comprising omega fatty acid | |
JP6251440B1 (en) | Olive oil composition for beverage, olive oil beverage and method for producing them | |
US6103755A (en) | Foodstuff with prophylactic and/or healing effect and process for its production | |
EA026141B1 (en) | Instant functional food product | |
TW201141466A (en) | Methods of modulating inflammation in preterm infants using carotenoids | |
KR20100041062A (en) | Method for preparing flavor enhancing tomato jam | |
Rudavska et al. | New products for school food of the iodine deficiency biogeochemical provinces | |
Fischer | The Eczema Detox: The Low-chemical Diet for Eliminating Skin Inflammation | |
Cutting et al. | Stop that Heart Attack! | |
JP2015133942A (en) | Health drink and manufacturing method thereof | |
HAMED et al. | Nutrition and the Patient with Progressive Central Nervous System Disease | |
JP2006025769A (en) | Health food and method for maintaining health | |
KR20050040536A (en) | Greentea - soymilk compositions and methods for preparation thereof using isolated soy proteins | |
Booth | The Dietetic Role of Caloreen | |
TW201626901A (en) | Natural gavage feeding formula and its application on preparation of ready-to-eat pack |